Skip to content

Study · Not a test of the peptide alone · 2021

2 results

Effect of paracellular permeation enhancers on intestinal permeability of two peptide drugs, enalaprilat and hexarelin, in rats.

Dahlgren D, Olander T, Sjöblom M, Hedeland M, Lennernäs H

Acta pharmaceutica Sinica. B5 Jan 2021Cited by 18 (Europe PMC)

PMID34221875 (opens in a new tab)PMCIDPMC8245904 (opens in a new tab)DOI10.1016/j.apsb.2020.12.019 (opens in a new tab)PepBankPUB-34221875
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 01AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Pharmacokinetics

    In rat intestinal perfusion, the paracellular permeation enhancers chitosan and EDTA increased mucosal permeability of hexarelin and enalaprilat to a similar extent.

    In plain wordsIn rats, chitosan and EDTA increased gut wall passage of hexarelin and another peptide drug to a similar extent.

    Peptide
    Hexarelin
    Outcome
    IncreaseIntestinal permeability with paracellular permeation enhancers
    Study

    ratn: not reported in source

    Rat single-pass intestinal perfusion
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    The two paracellular permeation enhancers increased the mucosal permeability of both peptide drugs to a similar extent.
    1 context sentence
    Summary · context
    This was investigated using the rat single-pass intestinal perfusion model with concomitant blood sampling.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  2. 02AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Pharmacokinetics

    In rat intestinal perfusion, luminal hypotonicity did not affect lumen-to-blood transport of enalaprilat and hexarelin.

    In plain wordsIn rats, low salt concentration in the gut did not change transport of hexarelin and another peptide drug into blood.

    Peptide
    Hexarelin
    Outcome
    No significant changeLumen-to-blood transport under luminal hypotonicity
    Study

    ratn: not reported in source

    Rat single-pass intestinal perfusion
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    In contrast, luminal hypotonicity did not affect the lumen-to-blood transport of enalaprilat and hexarelin.
    1 context sentence
    Summary · context
    This was investigated using the rat single-pass intestinal perfusion model with concomitant blood sampling.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.